[HTML][HTML] Parkinson's disease and Fabry disease: clinical, biochemical and neuroimaging analysis of three pedigrees
MF Gago, O Azevedo, A Guimarães… - Journal of …, 2020 - content.iospress.com
Journal of Parkinson's Disease, 2020•content.iospress.com
Background: Sporadic Parkinson's disease (PD) patients have lower α-galactosidase A (α-
GAL A) enzymatic activity and Fabry disease (FD) patients potentially carry an increased risk
of PD. Objective: Determination of PD prevalence in FD and clinical, biochemical and
vascular neuroimaging description of FD pedigrees with concomitant PD.
GAL A) enzymatic activity and Fabry disease (FD) patients potentially carry an increased risk
of PD. Objective: Determination of PD prevalence in FD and clinical, biochemical and
vascular neuroimaging description of FD pedigrees with concomitant PD.
Abstract
Background: Sporadic Parkinson’s disease (PD) patients have lower α-galactosidase A (α-GAL A) enzymatic activity and Fabry disease (FD) patients potentially carry an increased risk of PD. Objective: Determination of PD prevalence in FD and clinical, biochemical and vascular neuroimaging description of FD pedigrees with concomitant PD.
content.iospress.com